このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

REVASC-PAD:末梢動脈疾患に対する制限血管運動 - テネシー大学医療センターにおける実現可能性調査 (REVASC-PAD)

REVASC-PAD:末梢動脈疾患に対する制限付き血管運動 - テネシー大学医療センターでの実現可能性調査

The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).

The main aims of the study are:

  1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups
  2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms
  3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups

調査の概要

研究の種類

介入

入学 (推定)

81

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Tiffany Johnson, Study Coordinator
  • 電話番号:+1865-305-4682
  • メール:thjohnson@utmck.edu

研究場所

    • Tennessee
      • Knoxville、Tennessee、アメリカ、37920
        • 募集
        • University of Tennessee Medical Center
        • 主任研究者:
          • Morgan Randall, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. 18 years of age or older
  2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)
  3. Ankle-brachial index (ABI) between 0.4 and 0.9.
  4. Eligible referral to cardiovascular or pulmonary rehabilitation
  5. Prior revascularization permitted if symptoms are stable and other criteria are met

Exclusion Criteria:

  1. Recent change in resting ECG suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event
  2. Unstable angina
  3. Uncontrolled cardiac arrhythmias
  4. Symptomatic severe aortic stenosis or other significant valvular disease
  5. Decompensated symptomatic heart failure
  6. Acute pulmonary embolism or infarction
  7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)
  8. Acute myocarditis or pericarditis
  9. Acute thrombophlebitis
  10. Physical disability precluding safe or adequate exercise performance
  11. Significant electrolyte abnormalities
  12. Clinically significant tachyarrhythmias or bradyarrhythmias
  13. High-degree atrioventricular block
  14. Atrial fibrillation with uncontrolled ventricular response
  15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of >25 mmHg
  16. Known active aortic dissection
  17. Severe resting arterial hypertension (SBP>200mmHg or DBP >110 mmHg)
  18. Mental impairment preventing cooperation with study procedures
  19. Current pregnancy
  20. Moderate to severe peripheral neuropathy
  21. Open wounds or compromised skin near BFR cuff site
  22. Active DVT or thromboembolic event within the past year

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Blood Flow Restriction (BFR) Training

Participants perform supervised lower-body resistance training using pneumatic cuffs (Smart Cuff Pro or equivalent) applied to the proximal thighs. Cuffs are inflated to 60-80% of the participant's measured arterial occlusion pressure (AOP). Pressure is increased at Weeks 5 and 9 based on tolerance. Cuff inflation will not exceed 80% of limb occlusion pressure. Cuffs will be immediately deflated if participants' vitals suggest poor tolerance.

All BFR resistance sessions will include two standardized lower-extremity exercises: seated calf raises and standing calf raises. Each session will follow this protocol:

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. 30 seconds rest between sets, with the cuff remaining inflated
  3. Load set at 20-35% of 1RM
  4. Cuff deflated immediately after the fourth set or after 6 continuous minutes of inflation, whichever comes first
アクティブコンパレータ:Low-Load Traditional Resistance Training (LL-RT)

Participants perform the same two calf exercises (seated and standing calf raises) without BFR cuffs. If participants demonstrate the ability to complete all prescribed repetitions without undue strain, planned load progressions of approximately 5-10% 1RM will be introduced at Weeks 5 and 9. Repetitions and sets will remain fixed to match the BFR protocol.

Two resistance exercises (seated and standing calf raises) using the same repetition structure

  1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions
  2. Load set at 20-35% of 1RM
  3. 30 seconds rest between sets
  4. No BFR cuffs will be used
アクティブコンパレータ:High-Load Traditional Resistance Training (HL-RT)

Participants in this group will perform seated and standing calf raises following a more conventional strength training model. Similar to the other groups, if participants can complete their prescribed workload without excessive strain, two planned load progressions (5-10% 1RM) will be applied at Weeks 5 and 9. Repetitions and sets will remain fixed to preserve consistency in training structure across groups. This group serves as a benchmark for conventional resistance training in clinical and musculoskeletal rehabilitation populations.

Each session includes:

  1. 3 sets of 8-12 repetitions
  2. Load set at 60-70% of 1RM
  3. Rest periods of 60-90 seconds between sets
  4. No BFR cuffs will be used

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Walking Function
時間枠:Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in walking distance measured by the Six-Minute Walk Test (6MWT) from baseline to end of intervention and 3-month follow-up visit.

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (1)
時間枠:Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in health-related quality of life as assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (2)
時間枠:Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in depressive symptoms as assessed by Patient Health Questionnaire-9 (PHQ-9) from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)
Quality of Life (QoL) (3)
時間枠:Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Change in self-reported walking function and symptom burden assessed by using REVASC-PAD Walking Questionnaire from baseline to post-intervention and 3-month follow-up

Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

二次結果の測定

結果測定
メジャーの説明
時間枠
Claudication Onset Time (COT) during 6MWT
時間枠:Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention

Time to onset of claudication symptoms during 6MWT at baseline, post-intervention, and 3-month follow-up

Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention
Ratings of Perceived Exertion (RPE), Dyspnea, and Claudication Pain
時間枠:Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)

Session-based self-reported symptom ratings collected at each supervised exercise session from Visit 2 to end of intervention (approximately 8 to 12 weeks). These ratings assess exercise tolerance and symptom burden during blood flow restriction training.

Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)
Adverse Event (AE) and Serious Adverse Event (SAE) Rates
時間枠:Baseline to 3-month follow-up

Number and rate of adverse events and serious adverse events occurring during the study period.

Baseline to 3-month follow-up
Enrollment, Retention, and Adherence Rates
時間枠:Baseline to 3-month follow-up

Rates of successful enrollment, participant retention at post-intervention and 3-month follow-up, and adherence to prescribed exercise sessions

Baseline to 3-month follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年4月27日

一次修了 (推定)

2027年4月27日

研究の完了 (推定)

2027年4月27日

試験登録日

最初に提出

2025年10月24日

QC基準を満たした最初の提出物

2025年10月28日

最初の投稿 (実際)

2025年10月31日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年11月3日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 5460
  • Institutional Review Board (その他の識別子:The University of Tennessee Health Science Center)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する